Company / Current Liabilities
Vistagen Therapeutics, Inc. Current Liabilities History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$4.6M
FY2023
5-year range
$1.4M / $5.8M
FY2019-FY2023
Trend
-20.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 8 years, ranging from $1M in FY2017 to $6M in FY2022.
Based on SEC 10-K filings.
$5M in FY2023 with a 5-year CAGR of +25.6%.
Increased from $4M to $5M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +25.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +25.6%, indicating consistent growth.
- In FY2023, current liabilities decreased 20.8% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $4.6M | -20.8% |
| FY2022 | $5.8M | +37.6% |
| FY2021 | $4.2M | +187.2% |
| FY2018 | $1.5M | +6.7% |
| FY2017 | $1.4M | -43.4% |
| FY2014 | $2.4M | -24.1% |
| FY2012 | $3.2M | +0.0% |
| FY2011 | $3.2M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026